For real-time updates on GLYC, beat the news and login or try Benzinga Pro.
GlycoMimetics GLYC today had a large opening gap of -123.77%.
Photo taken from the Opening Gap Signals tool inside Benzinga Pro.
Why Is GLYC Moving?
GlycoMimetics shares are trading lower after the company announced Pfizer’s Phase 3 clinical trial evaluating Rivipansel in sickle cell did not meet its primary or key secondary endpoints.
Photo taken from the ‘Why Is It Moving?’ Details tool inside Benzinga Pro.
For live updates on GLYC log in or try Benzinga Pro today.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.